What is Endovascular Engineering?
Headquartered in Menlo Park, California, Endovascular Engineering operates at the intersection of advanced biomedical engineering and clinical intervention. The company is dedicated to addressing the critical healthcare challenge of venous thromboembolism through the design and manufacturing of next-generation mechanical thrombectomy technologies. By focusing on high-precision, minimally invasive solutions, the firm aims to improve patient outcomes while simultaneously reducing the economic burden on healthcare systems. Its market position is bolstered by a sophisticated intellectual property portfolio and a clear focus on high-acuity vascular care, positioning it as a key player in the evolving MedTech ecosystem.
How much funding has Endovascular Engineering raised?
Endovascular Engineering has raised a total of $122M across 2 funding rounds:
Series B
$42M
Series C
$80M
Series B (2025): $42M with participation from Santé Ventures, S3 Ventures, 415 Capital, and M&L Healthcare
Series C (2026): $80M led by Panakes Partners, Santé Ventures, Gilde Healthcare, Venture Capital, S3 Ventures, and Norwest Venture Partners
Key Investors in Endovascular Engineering
Santé Ventures
A specialized investment firm managing over $1 billion, focusing on innovative Biotech, Medtech, and Healthtech companies to enhance patient outcomes.
S3 Ventures
The largest venture capital firm focused on Texas, providing flexible, long-term capital to high-impact startups in the healthcare technology and digital experience sectors.
Gilde Healthcare
A European-based investment firm managing over 1.4 billion euros, dedicated to supporting businesses that enable better care at lower costs through specialized venture and growth strategies.
What's next for Endovascular Engineering?
With the infusion of this recent capital, Endovascular Engineering is poised to scale its operational infrastructure and expand its clinical trial footprint. The strategic roadmap likely includes accelerating regulatory approval pathways and enhancing manufacturing capabilities to meet anticipated market demand. As the company moves deeper into its growth phase, the focus will shift toward establishing commercial partnerships and refining its go-to-market strategy for its flagship venous thromboembolism solutions. Investors remain optimistic that the firm's technical expertise will translate into significant market share gains within the vascular intervention sector.
See full Endovascular Engineering company page
